Vertex Pharmaceuticals (VRTX) FY2025 10-K Annual Report
Vertex Pharmaceuticals (VRTX) 10-K annual report for fiscal year 2025, filed with SEC EDGAR on Feb 13, 2026. This page provides AI-powered analysis including business overview, management discussion & analysis (MD&A), risk factors, and key financial data such as revenue, net income, gross margin, operating margin, and return on equity (ROE) extracted from XBRL.
Vertex Pharmaceuticals FY2025 10-K Analysis
Business Overview
- • Core business model: Biopharmaceutical company focused on developing and commercializing transformative medicines
- • Emphasis on enhanced cybersecurity governance with dedicated CISO and quarterly Board updates
- • Cybersecurity led by CISO with 35+ years’ experience, including federal advisory roles, highlighting heightened focus on cyber risk
- • Cybersecurity team holding top certifications conducts regular vulnerability scans, penetration tests, and threat intelligence analysis
- • Cybersecurity risk oversight integrated into executive management reporting chain up to CEO, reflecting strategic prioritization
Management Discussion & Analysis
- • Revenue $12.0B in 2025, up 9% YoY from $11.0B in 2024; TRIKAFTA/KAFTRIO sales $10.3B (1% increase), ALYFTREK $837.8M launched in 2025
- • Operating margin approx. 34.7% in 2025 vs 13.8% cost of sales (13.8% of net product revenues), slight improvement from 13.9% in 2024; R&D + SG&A expenses $5.7B up from $5.1B
- • Best performing segment: TRIKAFTA/KAFTRIO revenues $10.31B (+1%); Worst: Newly launched CASGEVY $115.8M and JOURNAVX $59.6M, small but growing
- • Cash, cash equivalents, marketable securities increased to $12.3B in 2025 from $11.2B in 2024; repurchased shares partially offset; R&D expenses $3.91B (+8%), cost of sales $1.65B (+8%)
- • 2026 Outlook: Continued CF revenue growth led by ALYFTREK globally, increased CASGEVY and JOURNAVX revenues; pipeline regulatory submissions expected H1 2026; watch ongoing royalty dispute on ALYFTREK royalty rate
Risk Factors
- • Regulatory risk: Impact of Colorado PDAB affordability review on TRIKAFTA pricing with potential upper payment limits under the 2023 state program
- • Macroeconomic risk: Ex-U.S. reimbursement delays and government cost-containment efforts impacting pricing and revenue in various international markets
- • Operational risk: CASGEVY manufacturing cost significantly higher as a percentage of revenue versus CF medicines, with complex cell collection and administration processes
- • Competitive risk: Pressure from lower-cost and advanced competitors in acute and peripheral neuropathic pain markets threatening uptake of JOURNAVX
- • Financial risk: Concentrated revenue dependence on CF medicines, exposing business to risks from manufacturing, safety, market acceptance, and pricing challenges
Vertex Pharmaceuticals FY2025 Key Financial MetricsXBRL
Revenue
$12.0B
▲ +8.9% YoY
Net Income
$4.0B
▲ +838.1% YoY
Operating Margin
34.8%
▲ +3689bp YoY
Net Margin
32.9%
▲ +3780bp YoY
ROE
21.2%
▲ +2444bp YoY
Total Assets
$25.6B
▲ +13.8% YoY
EPS (Diluted)
$15.32
▲ +836.5% YoY
Operating Cash Flow
$3.6B
▲ +837.2% YoY
Source: XBRL data from Vertex Pharmaceuticals FY2025 10-K filing on SEC EDGAR. All figures in USD.
Get deeper insights on Vertex Pharmaceuticals
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.